{"nct_id":"NCT02089685","title":"Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)","status":"COMPLETED","status_verified_date":"2022-08","start_date":"2014-03-17","start_date_type":"ACTUAL","primary_completion_date":"2021-04-01","primary_completion_date_type":"ACTUAL","completion_date":"2021-04-01","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["MRK"]}